Wave Life Sciences, Inc.

Wave Life Sciences Inc's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Wave Life Sciences Inc has 193.10M shares outstanding.

As of June 30, 2026, Wave Life Sciences Inc maintains a current ratio of 9.99, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Wave Life Sciences Inc posted a negative return on equity (ROE) of -68.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -49.95, reflecting losses generated across the asset base. The company generates approximately 184,727.16 in revenue per employee across its workforce of 309.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Wave Life Sciences Inc generated 57.22M in revenue and converted that into -177.22M in net income, yielding earnings per share of -0.94. EBITDA reached -182.72M, while operating income came in at -190.75M.

As of June 30, 2026, Wave Life Sciences Inc holds 429.42M in cash and equivalents against 38.15M in total debt, resulting in a net debt position of -322.12M. Total book value stands at 396.97M, with working capital of 399.74M providing operational flexibility.

Wave Life Sciences Inc produced -167.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.37M in capital expenditures, free cash flow totaled -169.06M - equivalent to -0.90 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -333.36 and net profit margin of -309.73 provide insight into operational efficiency.